Nature of Operations and Basis of Presentation - Additional Information (Details)										3 Months Ended		9 Months Ended
	Oct. 12, 2021 USD ($)	Oct. 06, 2021 USD ($)	Oct. 04, 2021 USD ($) Tranche	Mar. 19, 2021 USD ($)	Jan. 25, 2021 USD ($)	Jul. 24, 2020 USD ($) $ / shares shares	Apr. 30, 2020 USD ($) shares	Mar. 18, 2020 USD ($)	Nov. 09, 2018 USD ($)	Sep. 30, 2021 USD ($) $ / shares shares	Jun. 30, 2021 USD ($)	Sep. 30, 2021 USD ($) $ / shares shares	Sep. 30, 2020 USD ($)	Dec. 31, 2020 USD ($)
Organization Consolidation and Presentation of Financial Statement [Line Items]
Accumulated deficit										$ 110,089,311		$ 110,089,311		$ 99,135,961
Cash and cash equivalents										14,151,496		14,151,496		5,761,568
Net cash used in operating activities												1,285,339	$ (13,147,533)
Proceeds from issuance of common stock, net of issuance costs												3,139,047	$ 6,667,091
Reimbursement payment				$ 14,000,000.0
Development payments				10,000,000.0
Current liabilities										30,385,765		30,385,765		$ 6,145,546
Deferred collaboration funding										17,771,957		17,771,957
Liability related to securities class action and stockholder derivative actions settlements and legal costs										$ 9,200,000		$ 9,200,000
Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock | shares										0		200,000
Issuance of common stock, price per share | $ / shares										$ 2.47		$ 2.47
Proceeds from issuance of common stock gross												$ 500,000
Proceeds from issuance of common stock, net of issuance costs												500,000
Remaining obligation										$ 12,100,000		$ 12,100,000
Number of shares, company may sell on any single business day | shares							50,000
Maximum amount of Common stock at time of sale, per regular purchase							$ 1,000,000.0
Issuance of common stock for commitment fee, shares | shares							148,148
Stock to be issued value on certain limitation and condition							$ 12,100,000
Collaboration Agreement | Relief
Organization Consolidation and Presentation of Financial Statement [Line Items]
Upfront non-refundable payment received					$ 1,000,000.0
Reimbursement payment				14,000,000.0	14,000,000.0
Guarantee for substantive review food and drug application					0
Milestone payment to be received				$ 6,000,000.0	6,000,000.0
Collaboration Agreement | Relief | First Development Payment
Organization Consolidation and Presentation of Financial Statement [Line Items]
Development payments subject new drug application											$ 10,000,000.0
Collaboration Agreement | Subsequent Event | Relief | Second Development Payment
Organization Consolidation and Presentation of Financial Statement [Line Items]
Potential proceeds from development payments subject to new drug application			$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application	$ 5,000,000.0
Number of tranches in developments payments to be made | Tranche			2
Waiver and Agreement | Subsequent Event | Relief | Second Development Payment
Organization Consolidation and Presentation of Financial Statement [Line Items]
Potential proceeds from second tranche of development payments subject to new drug application		$ 5,000,000.0
Second tranche of development payment, expiry date		Jan. 14, 2022
Written notice period (in business days) for second tranche of development payment		15 days
General and Administrative | Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Fair value of the commitment fee shares, recorded to general and administrative expense along with other costs							400,000
Weighted Average | Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, price per share | $ / shares										$ 2.47		$ 2.47
Maximum | Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Shares value might be issued under agreement							$ 15,000,000.0
Number of shares, company may sell on any single business day | shares							100,000
Maximum | Collaboration Agreement | Relief
Organization Consolidation and Presentation of Financial Statement [Line Items]
Development payments					$ 20,000,000.0
At-the-Market Facility
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock | shares										0		877,107
Proceeds from issuance of common stock gross												$ 2,800,000
Common stock offering costs												200,000
Proceeds from issuance of common stock, net of issuance costs												$ 2,600,000
At-the-Market Facility | Weighted Average
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, price per share | $ / shares										$ 3.1692		$ 3.1692
At-the-Market Facility | Maximum
Organization Consolidation and Presentation of Financial Statement [Line Items]
Aggregate offering price of common stock								$ 50,000,000.0	$ 50,000,000.0
Private Placement | Directors, Officers and Employees
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock | shares						244,998
Issuance of common stock, price per share | $ / shares						$ 3.50
Proceeds from issuance of common stock, net of issuance costs						$ 900,000